AnalystBook Research · Company Intelligence

Hyperfine, Inc.

HYPRNasdaq

Built from Hyperfine, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

The read at a glance

Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.

  • Distress risk · Altman Z-Score -16.12 distress zone — historically elevated failure riskWatch
  • Earnings-manipulation signal · Beneish M -3.46 no flag raisedOK
  • Earnings quality 64/100 worth a closer lookWatch

Where the revenue comes from

Fiscal 2025, as Hyperfine, Inc. reports it. History and quarterly detail are in the app.

  • Product$11.4M
  • Service$2.2M

Leadership changes

From Hyperfine, Inc.'s own filings, the day they're filed.

  • Khan Siddiqui · Chief Medical Officer · departureeff. 2023-09-30
  • Thomas Teisseyre · Chief Operating Officer · appointmenteff. 2023-07-24
  • Daniel J. Wolterman · Chairperson · appointment

Latest filings

  • 8-K · Company announcement2026-08-06
  • 10-Q · Quarterly report2026-08-06
  • 8-K · Company announcement2026-05-21
  • 8-K · Company announcement2026-05-12
  • 10-Q · Quarterly report2026-05-12
In the full recordFree for 14 days
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Hyperfine, Inc., every answer cited to the official filings🔒
  • The Intelligence Brief — added when Hyperfine, Inc.'s brief passes our SEC-figure check🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.